Screen and prioritise legacy APIs for a tailored environmental assessment
Identify potential hazards associated with APIs in development and explore the options to steer the design process in a greener direction
Make relevant environmental data on APIs more visible and accessible to all stakeholders
Radboud University Nijmegen | NL |
University of York | UK |
ECT Oekotoxikologie GmbH | DE |
Rijksinstituut voor Volksgezondheid en Milieu | NL |
Istituto di Ricerche Farmacologiche Mario Negri | IT |
Eidgenoessische Anstalt Fuer Wasserversorgung Abwasserreinigung Und Gewässerschutz | CH |
Leuphana Universitat Luneburg | DE |
University of Exeter | UK |
Teamit Research SL | SP |
Simomics Limited | UK |
ECOLOGIC INSTITUT gemeinnützige GmbH | DE |
Fraunhofer Gesellschaft Zur Foerderung der Angewandten Forschung E.V. | DE |
Helsingin Yliopisto | FI |
Goeteborgs Universitet | SE |
AstraZeneca AB | SE |
GlaxoSmithKline Research and development Ltd. | UK |
F. Hoffmann-La Roche | CH |
BAYER AKTIENGESELLSCHAFT | DE |
BRISTOL-MYERS SQUIBB COMPANY CORP | US |
NOVARTIS Pharma AG | CH |
SANOFI-Aventis Recherche & Developpement | FR |
Institute de Recherches Internationales SERVIER | FR |
Eli Lilly and Company Limited | DE |
The European Medicines Agency | NL |
Merck Sharp & Dohme Corp | US |
Funding period: 01/09/2020 to 30/08/2026. Years: 6 (2020-26)
EFPIA companies: 10. Academic & SMEs: 15
Total Budget: € 9 Million
IMI contribution: € 4.5 Million (in cash). EFPIA contribution: € 4.5 Million (in kind)
Project Coordinator: Radboud University Nijmegen
Project Leader: AstraZeneca AB
“PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 875508. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA”.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences.